Equities analysts expect Transenterix Inc (NASDAQ:TRXC) to report $110,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Transenterix’s earnings, with estimates ranging from $60,000.00 to $150,000.00. Transenterix posted sales of ($999,000,000.00) during the same quarter last year, which suggests a positive year over year growth rate of 100%. The firm is scheduled to report its next quarterly earnings report on Friday, August 4th.
According to Zacks, analysts expect that Transenterix will report full-year sales of $110,000.00 for the current fiscal year, with estimates ranging from $6.26 million to $8.6 million. For the next financial year, analysts expect that the business will post sales of $33.66 million per share, with estimates ranging from $16.6 million to $49.9 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Transenterix.
A number of equities analysts have recently issued reports on TRXC shares. Zacks Investment Research upgraded Transenterix from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research note on Wednesday, May 10th. B. Riley downgraded Transenterix to a “neutral” rating and set a $0.70 price target on the stock. in a research note on Tuesday.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/06/20/transenterix-inc-trxc-expected-to-post-quarterly-sales-of-110000-00-updated-updated-updated-updated.html.
Shares of Transenterix (NASDAQ:TRXC) traded down 0.0182% during mid-day trading on Thursday, reaching $0.5503. The company had a trading volume of 858,448 shares. Transenterix has a one year low of $0.52 and a one year high of $2.33. The company has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.27. The company’s market capitalization is $81.74 million.
In other news, Director Richard C. Pfenniger, Jr. purchased 100,000 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were purchased at an average cost of $0.54 per share, for a total transaction of $54,000.00. Following the purchase, the director now directly owns 148,000 shares in the company, valued at approximately $79,920. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.